

Status: Currently Official on 16-Feb-2025  
 Official Date: Official as of 01-Aug-2017  
 Document Type: USP Monographs  
 DocId: GUID-D7F54681-7601-4221-B3B5-7BF86793DEAB\_1\_en-US  
 DOI: [https://doi.org/10.31003/USPNF\\_M56210\\_01\\_01](https://doi.org/10.31003/USPNF_M56210_01_01)  
 DOI Ref: yd3yi

© 2025 USPC  
 Do not distribute

# Neomycin and Polymyxin B Sulfates, Bacitracin Zinc, and Hydrocortisone Ophthalmic Ointment

## DEFINITION

Neomycin and Polymyxin B Sulfates, Bacitracin Zinc, and Hydrocortisone Ophthalmic Ointment is a sterile ointment containing Neomycin Sulfate, Polymyxin B Sulfate, Bacitracin Zinc, and Hydrocortisone. It contains the equivalent of NLT 90.0% and NMT 140.0% of the labeled amounts of neomycin, polymyxin B, and bacitracin, and NLT 90.0% and NMT 110.0% of the labeled amount of hydrocortisone ( $C_{21}H_{30}O_5$ ).

## IDENTIFICATION

- **A. [THIN-LAYER CHROMATOGRAPHIC IDENTIFICATION TEST \(201BNP\)](#):** Meets the requirements
- **B.** The retention time of the hydrocortisone peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay for *Hydrocortisone*.

## ASSAY

### • NEOMYCIN

(See [Antibiotics—Microbial Assays \(81\)](#).)

**Sample solution:** Shake a portion of Ophthalmic Ointment in a separator with 50 mL of [ether](#). Extract with four 20-mL portions of *Buffer B.3*. Combine the aqueous extracts, and dilute with *Buffer B.3* to a suitable volume.

**Analysis:** Proceed as directed in the chapter. Dilute the *Sample solution* with *Buffer B.3* to obtain a *Test Dilution* having a neomycin concentration that is nominally equivalent to the median level of the standard.

**Acceptance criteria:** 90.0%–140.0%

### • POLYMYXIN B

(See [Antibiotics—Microbial Assays \(81\)](#).)

**Sample solution:** Shake a portion of Ophthalmic Ointment with 50 mL of [ether](#) in a separator. Extract with four 25-mL portions of *Buffer B.6*. Combine the aqueous extracts, and dilute with *Buffer B.6* to a suitable volume.

**Analysis:** Proceed as directed in the chapter. Dilute the *Sample solution* with *Buffer B.6* to obtain a *Test Dilution* having a concentration that is nominally equivalent to the median level of the standard (10 polymyxin B Units/mL). Add to each *Test Dilution* of the standard a quantity of [USP Neomycin Sulfate RS](#), dissolved in *Buffer B.6*, to obtain the same concentration of neomycin as in the *Test Dilution* of the sample.

**Acceptance criteria:** 90.0%–140.0%

### • BACITRACIN

(See [Antibiotics—Microbial Assays \(81\)](#).)

**Sample solution:** Shake a portion of Ophthalmic Ointment with 50 mL of [ether](#) in a separator. Extract with four 25-mL portions of [0.01 N hydrochloric acid](#). Combine the acid extracts, and dilute with [0.01 N hydrochloric acid](#) to a suitable volume.

**Analysis:** Proceed as directed in the chapter. Dilute the *Sample solution* with *Buffer B.1* to obtain a *Test Dilution* having a concentration that is nominally equivalent to the median level of the standard (1.0 bacitracin Unit/mL). If the *Sample solution* has a concentration of less than 100 bacitracin Units/mL, add hydrochloric acid to each *Test Dilution* of the standard to obtain the same concentration of hydrochloric acid as in the *Test Dilution* of the sample.

**Acceptance criteria:** 90.0%–140.0%

### • HYDROCORTISONE

**Mobile phase:** [Methanol](#), [glacial acetic acid](#), and [water](#) (500:1:500)

**Diluent:** [Methanol](#) and [water](#) (1:1)

**Standard solution:** 0.15 mg/mL of [USP Hydrocortisone RS](#) in *Diluent*

**Sample solution:** Transfer 1.5 g of Ophthalmic Ointment to a separator. Add 3 mL of [n-hexane](#), and warm gently on a steam bath with mild agitation until dissolved. Add 7 mL of [n-hexane](#), mix by swirling, and extract with four 15-mL portions of *Diluent*. Collect the extracts in a 100-mL volumetric flask, dilute with *Diluent* to volume, and mix. Filter the solution, rejecting the first 10 mL of the filtrate.

### Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

- Mode:** LC
- Detector:** UV 254 nm
- Column:** 3.9-mm × 30-cm; 10-µm packing [L1](#)
- Flow rate:** 2 mL/min
- Injection volume:** 10 µL

**System suitability**

**Sample:** *Standard solution*

**Suitability requirements**

**Relative standard deviation:** NMT 2.0%

**Analysis**

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of hydrocortisone ( $C_{21}H_{30}O_5$ ) in the portion of Ophthalmic Ointment taken:

Result =  $(r_U/r_S) \times (C_S/C_U) \times 100$

- $r_U$  = peak response from the *Sample solution*
- $r_S$  = peak response from the *Standard solution*
- $C_S$  = concentration of [USP Hydrocortisone RS](#) in the *Standard solution* (mg/mL)
- $C_U$  = nominal concentration of hydrocortisone in the *Sample solution* (mg/mL)

**Acceptance criteria:** 90.0%–110.0%

**SPECIFIC TESTS**

- **STERILITY TESTS (71):** Meets the requirements
- **OTHER REQUIREMENTS:** It meets the requirements for *Particulate and Foreign Matter* and *Container Contents* in [Ophthalmic Products—Quality Tests \(771\)](#), [Drug Product Quality, Universal Tests, Particulate and Foreign Matter](#) and [Container Contents](#).

**ADDITIONAL REQUIREMENTS**

- **PACKAGING AND STORAGE:** Preserve in collapsible ophthalmic ointment tubes.
- **USP REFERENCE STANDARDS (11).**
  - [USP Bacitracin Zinc RS](#)
  - [USP Hydrocortisone RS](#)
  - [USP Neomycin Sulfate RS](#)
  - [USP Polymyxin B Sulfate RS](#)

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC, AND HYDROCORTISONE OPHTHALMIC OINTMENT	<a href="#">Julie Zhang</a> Associate Science & Standards Liaison	BIO42020 Biologics Monographs 4 - Antibiotics
REFERENCE STANDARD SUPPORT	RS Technical Services <a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a>	BIO42020 Biologics Monographs 4 - Antibiotics

**Chromatographic Database Information:** [Chromatographic Database](#)

**Most Recently Appeared In:**  
Pharmacopeial Forum: Volume No. PF 39(5)

**Current DocID:** GUID-D7F54681-7601-4221-B3B5-7BF86793DEAB\_1\_en-US  
**DOI:** [https://doi.org/10.31003/USPNF\\_M56210\\_01\\_01](https://doi.org/10.31003/USPNF_M56210_01_01)  
**DOI ref:** [yd3yi](#)